Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, Efgartigimod alfa, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0111/2024

EMEA-003566-PIP01-23

Opinion/decision on a Paediatric investigation plan (PIP): Benlysta, belimumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Musculoskeletal and connective tissue disorders, PIP number: P/0109/2024

EMEA-003546-PIP01-23

EMEA-003563-PIP01-23

EMEA-003390-PIP01-23

EMEA-003562-PIP01-23

EMEA-003561-PIP01-23

EMEA-003559-PIP01-23

EMEA-003557-PIP01-23